The global epigenetics market size was US$ 1.14 billion in 2021. The global epigenetics market size is forecast to reach US$ 5.1 billion by 2030, growing at a compound annual growth rate (CAGR) of 14.9% during the forecast period from 2022 to 2030.

Epigenetics is a field of genetics that examines cellular and physiological feature changes produced by environmental or environmental variables that switch genes on and off and alter the cellular capacity to read genes without being influenced by genotype changes. Although the underlying DNA or RNA sequence stays unchanged, epigenetics produces changes in an organism's phenotype rather than genotype. Because epigenetic modifications are dynamic and change in response to environmental stimuli, they are vital for development.

Factors Influencing Market Growth

• The rising incidence of cancer, increasing funding and support for R&D, the growth of collaborations between academics, pharmaceutical and biotechnology companies, and the increasing application of epigenetics to non-oncology disorders are driving the global market.
• Standardization worries over epigenetics-based diagnostics and a lack of skilled professionals may slow down the overall market growth.
• Increasing the use of epigenetics for non-oncology applications and expanding the patient pool for customized medicine are forecast to offer lucrative opportunities for the global market.

Impact Analysis of COVID-19

The COVID-19 pandemic had a positive impact on the global market. Many clinics and hospitals worldwide have reconfigured to boost hospital capacity for COVID-19 patients. Due to the substantial increase in COVID-19 cases, non-essential procedures faced a backlog. However, in order to develop vaccines and therapies that directly target a virus's replicating mechanisms, researchers have begun to grasp how epigenetics may limit viral multiplication. As a result, the epigenetics business benefited from an increase in the number of epigenetic researchers and increased knowledge of epigenetic medications for the treatment of COVID-19 infection.

Regional Analysis

North America accounted for the largest epigenetics market size in 2021 and is forecast to maintain its dominance during the forecast period. As a result of the well-established healthcare infrastructure, the broad availability of advanced epigenetics products, the existence of prominent players, and the presence of trained medical professionals. 

The Asia Pacific region is forecast to have the highest growth rate during the forecast period. As a result of the rising awareness related to epigenetics, a surge in penetration of key players in emerging countries, and expansion in infrastructure for research and clinical settings. Thus, these factors are fueling the market growth in the region.

Leading Competitors

The leading prominent companies profiled in the global epigenetics market are:

• Abcam Plc.
• Active Motif, Incorporated
• Agilent Technologies, Incorporated
• Hologic Incorporated
• Illumina Incorporated
• Merck Millipore
• PerkinElmer, Incorporated
• QIAGEN N.V.
• Thermo Fisher Scientific Incorporated
• Zymo Research
• Other Prominent Players

Scope of the Report

The global epigenetics market segmentation focuses on Product, Application, End-User, and Region.

Segmentation based on Product

• Reagents
• Enzymes
• Instruments
• Kits

Segmentation based on Application

• Oncology
• Non-Oncology

Segmentation based on End-User

• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations

Segmentation based on Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa (MEA)
• UAE
• Saudi Arabia
• South Africa
• Rest of MEA
• South America
• Brazil
• Argentina
• Rest of South America